For biopharma
Find the right patients, faster.
Enrollment is the bottleneck in oncology trials. IGX Predict™ screens patients for driver mutations directly from H&E slides, in minutes instead of weeks, so you can identify and stratify candidates across every site, including settings without large sequencing panels.
The bottleneck
Trials don't fail for lack of science. They fail for lack of patients.
Eligible patients exist, but they go unfound. When molecular testing is slow, costly, or never ordered, the candidates who would qualify for a targeted trial are never identified, and enrollment stalls.
Screening from the H&E slide changes the funnel: every confirmed cancer case can be assessed for a driver mutation up front, before tissue is spent and before weeks are lost.
How it helps
Tissue-independent molecular screening, at trial scale.
Screen more, sooner
AI-based biomarker profiling predicts candidate mutations from existing slides, so investigators can assess far more patients, far earlier in the funnel.
Spare the tissue
Screening runs on the H&E image, leaving precious biopsy tissue intact for confirmatory testing and the trial itself.
Reach every site
Because it does not depend on a large NGS panel, screening extends to low-resource sites and underrepresented populations often left out of trials.
Predicted mutations are confirmed with a multi-gene panel or a low-cost single-gene assay, giving sponsors a fast, affordable path from whole-slide image to enrolled patient.
Proof in practice
An AKT mutation AI prediction, screened on slides.
- Faster trial executionAI mutation prediction from H&E speeds candidate identification across sites.
- Unified data, zero footprintConsultConnect aggregates results from every site into one cloud environment, no complex deployments.
- Lower cost and tissueReduced reliance on costly molecular testing translates into savings in time, tissue, and cost.
- A repeatable modelThe deployment establishes a scalable template for future biomarker-driven trials.
Source: PathPresenter success story, IGX Predict and ConsultConnect for AKT mutation prediction.
What you can screen
Screen across four cancer types.
From a single H&E slide, screen candidates for the drivers that matter in lung, breast, brain, and skin.
Why Imagenomix
Built to scale, built for trust.
Scalable infrastructure
The platform runs on cloud infrastructure built to grow with multi-site, multi-country trials, supported through the AWS Health Equity Initiative.
Representative by design
Models are trained across diverse patient populations so performance holds across racial and ethnic backgrounds, supporting more representative enrollment.
Grounded in evidence
Predictions are benchmarked against sequencing and backed by peer-reviewed work, with per-product validation behind every prediction.
Let us accelerate your next trial.
Tell us about your target and your sites, and we'll scope a screening approach with you.
Imagenomix Corp · New York, NY · Contact